[go: up one dir, main page]

FI853198L - Farmaceutiska kompositioner innehaollande i vatten instabila eller begraensat loesliga laekemedel och foerfarande foer framstaellning av dem. - Google Patents

Farmaceutiska kompositioner innehaollande i vatten instabila eller begraensat loesliga laekemedel och foerfarande foer framstaellning av dem.

Info

Publication number
FI853198L
FI853198L FI853198A FI853198A FI853198L FI 853198 L FI853198 L FI 853198L FI 853198 A FI853198 A FI 853198A FI 853198 A FI853198 A FI 853198A FI 853198 L FI853198 L FI 853198L
Authority
FI
Finland
Prior art keywords
loesliga
instabila
begraensat
vatten
eller
Prior art date
Application number
FI853198A
Other languages
English (en)
Other versions
FI853198A0 (fi
FI86140C (fi
FI86140B (fi
Inventor
Bernhard Willi Werner Mueller
Ulrich Brauns
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6217510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI853198(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI853198A0 publication Critical patent/FI853198A0/fi
Publication of FI853198L publication Critical patent/FI853198L/fi
Application granted granted Critical
Publication of FI86140B publication Critical patent/FI86140B/fi
Publication of FI86140C publication Critical patent/FI86140C/fi

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI853198A 1983-12-21 1985-08-20 Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel. FI86140C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19833346123 DE3346123A1 (de) 1983-12-21 1983-12-21 Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3346123 1983-12-21
EP8400417 1984-12-20
PCT/EP1984/000417 WO1985002767A1 (en) 1983-12-21 1984-12-20 Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation

Publications (4)

Publication Number Publication Date
FI853198A0 FI853198A0 (fi) 1985-08-20
FI853198L true FI853198L (fi) 1985-08-20
FI86140B FI86140B (fi) 1992-04-15
FI86140C FI86140C (fi) 1992-07-27

Family

ID=6217510

Family Applications (1)

Application Number Title Priority Date Filing Date
FI853198A FI86140C (fi) 1983-12-21 1985-08-20 Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel.

Country Status (17)

Country Link
EP (1) EP0149197B2 (fi)
JP (1) JPS61500788A (fi)
AT (1) ATE51145T1 (fi)
AU (1) AU565966B2 (fi)
CA (1) CA1222697A (fi)
CY (1) CY1689A (fi)
DE (2) DE3346123A1 (fi)
DK (1) DK175288B1 (fi)
FI (1) FI86140C (fi)
HK (1) HK131293A (fi)
HU (1) HU200943B (fi)
LU (1) LU90283I2 (fi)
NL (1) NL980009I1 (fi)
NO (1) NO2000007I1 (fi)
SG (1) SG24893G (fi)
WO (1) WO1985002767A1 (fi)
ZA (1) ZA8410042B (fi)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
IT1203968B (it) * 1987-04-24 1989-02-23 Bononi Ricerca Complessi di b-ciclodestrina ad attivita' antimicotica
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
ZA884592B (en) * 1987-08-31 1989-03-29 Warner Lambert Co Cyclodextrin complexes of bis-biguanido hexane compounds
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
CH676665A5 (fi) * 1987-12-22 1991-02-28 Glaxo Group Ltd
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2037385T3 (es) * 1988-01-14 1993-06-16 Akzo N.V. Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5637575A (en) * 1988-01-19 1997-06-10 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
EP0398925B1 (en) * 1988-01-19 1993-10-20 Children's Hospital Corporation Growth inhibiting agent and the use thereof
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
AU626538B2 (en) * 1988-01-19 1992-08-06 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5236944A (en) * 1988-03-28 1993-08-17 Janssen Pharmaceutica N.V. Compounds, compositions and anti-neoplastic methods
DE3815902A1 (de) * 1988-05-10 1989-11-23 Schwarz Pharma Gmbh Einschlussverbindungen des 1-(4-(2-(5-chloro-2-methoxybenzamido)ethyl) -phenylsulfonyl)-3-cyclohexylharnstoffs mit (alpha)-,ss-,(gamma)-cyclodextrinen, jeweils diese enthaltendes pharmazeutisches praeparat und verfahren zu deren herstellung
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
NL8801670A (nl) 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
WO1990001320A1 (en) * 1988-08-15 1990-02-22 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JP2929108B2 (ja) * 1988-10-28 1999-08-03 株式会社資生堂 化粧料および粉末化粧料
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
GB8910069D0 (en) * 1989-05-03 1989-06-21 Janssen Pharmaceutica Nv Method of topically treating acne vulgaris
JPH0737390B2 (ja) * 1989-08-29 1995-04-26 久光製薬株式会社 軟膏組成物
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
US5053240A (en) * 1989-10-24 1991-10-01 Kalamazoo Holdings, Inc. Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
FR2660309B1 (fr) * 1990-03-27 1992-07-17 Roussel Uclaf Nouveaux complexes de l'acide tiaprofenique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs derives.
JP2867162B2 (ja) * 1990-03-31 1999-03-08 株式会社資生堂 ピールオフ型パック化粧料
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
RU2108109C1 (ru) * 1990-10-04 1998-04-10 Мадаус АГ Способ получения комплекса силибинина с циклодекстрином, комплекс включения силибинина с циклодекстрином, фармацевтическая композиция антигепатотоксической активности и способ ее получения
LU87843A1 (fr) * 1990-11-15 1992-08-25 Cird Galderma Gel aqueux a base d'acide retinoique et d'hydroxypropyl-beta-cyclodextrine et son utilisation en medecine humaine et en cosmetique
JPH04351603A (ja) * 1991-05-29 1992-12-07 Toppan Printing Co Ltd β−シクロデキストリン誘導体
ATE196426T1 (de) * 1991-06-21 2000-10-15 Takeda Chemical Industries Ltd Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
DE69221252T2 (de) * 1991-10-16 1998-01-22 Schering Corp Lipophile Zusammensetzungen von Oligosaccharid-Antibiotikasalzen
IL103558A0 (en) 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals
US5254541A (en) * 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indole/cyclodextrin complex
DE4207922A1 (de) * 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
PT631578E (pt) * 1992-03-18 2001-11-30 Janssen Pharmaceutica Nv Estereoisomeros de itraconazol e saperconazol
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4227569C1 (de) * 1992-08-20 1994-06-09 Inst Chemo Biosensorik Verfahren zum empfindlichen enzymatischen Nachweis von anorganischem Phosphat
TW251236B (fi) * 1992-09-10 1995-07-11 Ciba Vision Ag
JP2879395B2 (ja) * 1992-10-26 1999-04-05 富士写真フイルム株式会社 ロダシアニン化合物及びシクロデキストリンを含有する抗癌性組成物
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
ZA941544B (en) * 1993-03-05 1994-10-31 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same.
CA2159717A1 (en) * 1993-03-31 1994-10-13 Elliot Barnathan Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor
DK94093D0 (da) * 1993-08-17 1993-08-17 Finn Molke Borgbjerg Lokalanaestetisk praeparat
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
AU1716995A (en) * 1994-03-18 1995-10-09 Ciba-Geigy Ag Aqueous solution of levocabastine for ophthalmic use
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
EP0760680A1 (en) * 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
FR2726765B1 (fr) * 1994-11-14 1996-12-20 Cis Bio Int Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
JP2920611B2 (ja) * 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
GB9605705D0 (en) 1996-03-19 1996-05-22 Pfizer Ltd Therapeutic agents
JP2000509374A (ja) 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DE69725704T2 (de) * 1996-08-09 2004-05-13 Alcon Manufacturing Ltd., Fort Worth Konservierungssysteme fur cyclodextrine enthaltende arzneimittel
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
EP0838225A3 (en) * 1996-10-25 1999-03-24 Hiji, Yasutake Aqueous local anesthetic solution
IL129575A (en) * 1997-03-26 2004-06-20 Janssen Pharmaceutica Nv Pills with a core coated with a fungicide and polymer
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
AU9650398A (en) * 1997-11-07 1999-05-31 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
WO1999033467A1 (en) 1997-12-31 1999-07-08 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
SE9902988D0 (sv) * 1999-08-24 1999-08-24 Astra Ab Chemical compounds
CN1223378C (zh) 2000-05-02 2005-10-19 施万制药 含有糖肽抗生素和环糊精的药物组合物
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
CA2463687A1 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
EP1476135A1 (en) 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
US6951846B2 (en) * 2002-03-07 2005-10-04 The United States Of America As Represented By The Secretary Of The Army Artemisinins with improved stability and bioavailability for therapeutic drug development and application
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
DE602004028448D1 (de) 2003-03-28 2010-09-16 Ares Trading Sa Orale zubereitungen enthaltend cladribin
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
EP2272503B1 (en) 2003-03-28 2013-03-20 Ares Trading S.A. Oral formulations of cladribine
CN1294912C (zh) * 2004-03-01 2007-01-17 上海医药工业研究院 伊曲康唑盐酸盐组合物及其冻干粉针
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
JPWO2006137433A1 (ja) * 2005-06-21 2009-01-22 わかもと製薬株式会社 レボカバスチンを可溶化させた水性薬剤
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
CA2660086C (en) 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
JP2010506942A (ja) * 2006-10-20 2010-03-04 イコス・コーポレイション Ｃｈｋ１阻害剤の組成物
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
AU2007321977A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
CN102014901A (zh) * 2008-02-28 2011-04-13 武田药品工业株式会社 药物组合物
NZ592927A (en) 2008-11-25 2013-07-26 Boehringer Ingelheim Vetmed PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
CN102499909B (zh) * 2011-12-27 2013-08-07 哈尔滨三联药业有限公司 伊曲康唑分散片及其制备方法
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
SG11201408565VA (en) * 2012-06-28 2015-02-27 Mcneil Ppc Inc Racecadotril liquid compositions
HK1220698A1 (zh) * 2013-03-13 2017-05-12 Seattle Genetics, Inc. 环糊精和抗体药物偶联物制剂
JP6272475B2 (ja) 2013-07-19 2018-01-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物
CA2926424C (en) * 2013-10-08 2018-01-09 Innopharma, Inc. Aprepitant oral liquid formulations
EA034054B1 (ru) 2013-12-04 2019-12-23 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные фармацевтические композиции пимобендана
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
LT3644999T (lt) * 2017-06-30 2023-03-10 Celgene Corporation 2-(4-chlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoracetamido kompozicijos ir panaudojimo būdai
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
KR102912248B1 (ko) * 2018-06-29 2026-01-15 로께뜨프레르 신규 히드록시프로필-β-사이클로덱스트린 및 이의 제조 방법
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
TN2023000266A1 (en) * 2021-05-26 2025-07-02 Daewoong Pharmaceutical Co Ltd Novel injectable formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN114195733B (zh) * 2022-01-07 2024-10-01 华东理工大学 一种抑制烯丙苯噻唑异构化的方法
GB2639834A (en) * 2024-03-22 2025-10-08 Remicine Ip B V Composition and method of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453259A (en) * 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
HU181703B (en) * 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids

Also Published As

Publication number Publication date
CY1689A (en) 1994-01-14
JPS61500788A (ja) 1986-04-24
DE3346123A1 (de) 1985-06-27
NO2000007I1 (no) 2000-09-21
CA1222697A (en) 1987-06-09
FI853198A0 (fi) 1985-08-20
DK175288B1 (da) 2004-08-09
EP0149197A2 (de) 1985-07-24
JPH0570612B2 (fi) 1993-10-05
AU3835285A (en) 1985-07-12
EP0149197B2 (de) 1997-01-08
AU565966B2 (en) 1987-10-01
HK131293A (en) 1993-12-03
FI86140C (fi) 1992-07-27
HUT40561A (en) 1987-01-28
DK359585D0 (da) 1985-08-07
EP0149197A3 (en) 1985-08-14
FI86140B (fi) 1992-04-15
ATE51145T1 (de) 1990-04-15
HU200943B (en) 1990-09-28
NL980009I1 (nl) 1998-05-06
SG24893G (en) 1993-08-06
LU90283I2 (fr) 1998-11-03
DK359585A (da) 1985-08-07
EP0149197B1 (de) 1990-03-21
ZA8410042B (en) 1985-09-25
DE3481680D1 (de) 1990-04-26
WO1985002767A1 (en) 1985-07-04

Similar Documents

Publication Publication Date Title
FI853198L (fi) Farmaceutiska kompositioner innehaollande i vatten instabila eller begraensat loesliga laekemedel och foerfarande foer framstaellning av dem.
ES2076150T3 (es) Derivados de 3-alcoxi-2-hidroxipropil-celulosa y su uso en composiciones para la edificacion.
ES2144390T3 (es) Derivados de n-fenilpirazol.
IL56369A (en) Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
FI792009A7 (fi) 3-aminopropoksiaryylijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset.
BR9709654A (pt) Derivados da tiazolidina-2,4-diona substituídos seus processos de obtenção e as composições farmacêuticas que os contêm
FI843560A7 (fi) Mevalonolaktonin analogeja ja niiden johdannaisia, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia yhdistelmiä ja niide n käyttö farmaseuttisina aineina.
NO842665L (no) Biopolymerer og fremgangsmaate for deres fremstilling
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
NO914077D0 (no) Galaktomannanderivater for omhylling eller innleiring av aktive bestanddeler i legemidler
IT1195267B (it) Derivati teofillinmetildiossolanici,procedimento per la loro preparazione e relative composizioni farmaceutiche
MX9203613A (es) Derivados de adenosina y composiciones farmaceuticas que los contienen.
FI834061A0 (fi) 2-piperazinylkinazolinderivat, framstaellning av dem och farmaceutiska kompositioner innehaollande dem
IT8221801A0 (it) Derivati di 1, 2, 3,4-tetraidronaftalene, procedimentodi preparazione e relative composizioni farmaceutiche.
NO913502L (no) Kompositt for anvendelse som hoeyenergi-sprengstoff eller drivmiddel.
IT8022188A0 (it) Derivati nicotinici di glucosamina, procedimento per la preparazione e relative composizioni farmaceutiche.
IT1157301B (it) Derivati di apovincaminolo, relativo procedimento di preparazione e composizioni farmaceutiche contenenti gli stessi
MX9102683A (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IT8123611A0 (it) Derivati di amminotioli, loro preparazione e loro impiego e anche composizioni contenenti questi derivati.
FR2531084B1 (fr) Nouveaux derives de la 7-(4-pyridyl)-1,8-naphtyridine, medicament et compositions pharmaceutiques en contenant
IT8422568A0 (it) Diidroarilossialchilammino-1,2,4-trprocedimento per la preparazione di iazolo. derivati di
IT8124843A0 (it) Derivati salicilici di alfa-mercaptopropionilglicina, procedimento per la loro preparazione e relative composizioni farmaceutiche.
ATE7385T1 (de) Derivate von 2-hydroxyoxalsaeureanilid und deren salze, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
IT8520439A0 (it) Preparazione e composizioni derivati del bornano, loro terapeutiche contenenti gli stessi.
MX9203564A (es) Derivados de tiazolidina, su preparacion y composiciones que los contienen.

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L127

Extension date: 20091220

FG Patent granted

Owner name: JANSSEN PHARMACEUTICA N.V.